Brain-specific angiogenesis inhibitor 1 (BAI1) antibodies and uses thereof
The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment.
1. An antibody, or antigen-binding fragment thereof, that binds to human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, wherein the antibody, or antigen-binding fragment thereof, comprises:
a first complementarity determining region (CDR) in the variable heavy (VH) chain (VH-CDR1) comprising an amino acid sequence according to SEQ ID NO:7;
a second CDR in the VH chain (VH-CDR2) comprising an amino acid sequence according to SEQ ID NO:8;
a third CDR in the VH chain (VH-CDR3) comprising an amino acid sequence according to SEQ ID NO:9;
a first CDR in the variable light (VL) chain (VL-CDR1) comprising an amino acid sequence according to SEQ ID NO:10;
a second CDR in the VL chain (VL-CDR2) comprising an amino acid sequence according to SEQ ID NO:11; and
a third CDR in the VL chain (VL-CDR3) comprising an amino acid sequence according to SEQ ID NO:12.
2. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody, or antigen-binding fragment thereof, comprises a VH chain comprising an amino acid sequence according to SEQ ID NO:1.
3. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody, or antigen-binding fragment thereof, comprises a VL chain comprising an amino acid sequence according to SEQ ID NO:4.
4. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody, or antigen-binding fragment thereof, comprises a VH chain comprising an amino acid sequence according to SEQ ID NO:1 and comprises a VL chain comprising an amino acid sequence according to SEQ ID NO:4.
5. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody is an IgM or IgG antibody.
6. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody, or antigen-binding fragment thereof, is humanized.
7. The humanized antibody, or antigen-binding fragment thereof, according to claim 6 , wherein the humanized antibody, or antigen-binding fragment thereof, comprises a heavy chain comprising an amino acid sequence according to SEQ ID NO:13.
8. The humanized antibody, or antigen-binding fragment thereof, according to claim 6 , wherein the humanized antibody, or antigen-binding fragment thereof, comprises a light chain comprising an amino acid sequence according to SEQ ID NO:14.
9. The humanized antibody, or antigen-binding fragment thereof, according to claim 6 , wherein the humanized antibody, or antigen-binding fragment thereof, comprises a heavy chain comprising an amino acid sequence according to SEQ ID NO:13, and comprises a light chain comprising an amino acid sequence according to SEQ ID NO:14.
10. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody, or antigen-binding fragment thereof, is conjugated to an effector moiety.
11. The antibody, or antigen-binding fragment thereof, according to claim 10 , wherein the effector moiety is a detectable label, a cytotoxic agent, a chemotherapeutic agent, or a nucleic acid molecule.
12. The antibody, or antigen-binding fragment thereof, according to claim 11 , wherein the antibody, or antigen-binding fragment thereof, comprises from 3 to 5 maytansinoid molecules per antibody, or antigen-binding fragment thereof.
13. The antibody, or antigen-binding fragment thereof, according to claim 11 , wherein the nucleic acid molecule is a single layer nucleic acid carrier, a 1.5 layer nucleic acid carrier, a two layer nucleic acid carrier, a 2.5 layer nucleic acid carrier, or a three layer nucleic acid carrier.
14. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antigen-binding fragment is an Fab, an F(ab′)2, an Fv, an scFv, an scFv-Fc, a diabody, or a minibody fragment.
15. A pharmaceutical composition comprising the antibody, or antigen-binding fragment thereof, according to claim 1 and a pharmaceutically acceptable carrier.
16. An isolated nucleic acid molecule encoding the VH chain of the antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence according to SEQ ID NO:2 or SEQ ID NO:3.
17. An isolated nucleic acid molecule encoding the VL chain of the antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the nucleic acid molecule comprises a nucleotide sequence according to SEQ ID NO:5 or SEQ ID NO:6.
18. A method of detecting a cell expressing BAI1, the method comprising contacting the cell with the antibody, or antigen-binding fragment thereof, according to claim 1 , and detecting the antibody, or antigen-binding fragment thereof.